All Publications
3 min read

Solstice / Element Solutions $14.5B Acquisition: Transaction Update — July 12, 2026 | ULF New York

M&A & Corporate Transactions

Solstice / Element Solutions $14.5B Acquisition: Transaction Update — July 12, 2026

A follow-up update on the Solstice Advanced Materials / Element Solutions definitive agreement. The cash-and-stock transaction — $10.00 per share plus 0.500 Solstice shares, representing approximately 15% premium to Element Solutions' July 2 closing price — remains on track for a first-half 2027 close. A KAP scan as of July 12, 2026 shows no new Turkish public company disclosures in the merger, demerger, or tender offer categories.

U
ULF New York
3 min read

Transaction Update — July 12, 2026

This note provides a follow-up update on the Solstice Advanced Materials / Element Solutions definitive agreement announced on July 6, 2026. No material changes to the transaction terms have been publicly disclosed as of this date.

Transaction Structure — Key Terms

Element Solutions shareholders will receive, for each Element Solutions share:

  • $10.00 in cash, and
  • 0.500 shares of Solstice Advanced Materials

The implied per-share value of approximately $50.10 represents a premium of approximately 15% to Element Solutions' closing price on July 2, 2026. Following closing, Element Solutions shareholders are expected to own approximately 44% of the combined company.

The cash consideration will be funded through existing resources and new debt. Solstice has secured an initial $4.7 billion bridge financing commitment from Goldman Sachs.

The combined company will operate under the Solstice name.

Strategic Context

The transaction combines Solstice's refrigerant gases, high-performance materials, and nuclear fuel cycle operations with Element Solutions' semiconductor and electronics chemicals. The resulting platform will operate across critical segments of the AI supply chain: semiconductor manufacturing, advanced chip packaging, electronics assembly, thermal management, and data center cooling.

Combined 2025 pro forma net sales are approximately $6.8 billion. Management targets more than $180 million in annual net synergies by year three post-closing, with adjusted earnings per share accretion from year one.

Regulatory and Process Timeline

Both companies' boards of directors unanimously approved the transaction. Closing is expected in the first half of 2027, subject to:

  • Approval by shareholders of both Solstice and Element Solutions,
  • Required antitrust and other regulatory clearances, and
  • Customary closing conditions.

Because the transaction includes a share consideration component, Solstice will file a Form S-4 registration statement with the SEC, incorporating a joint proxy statement/prospectus for both shareholder votes.

Given the transaction size, HSR pre-merger notification will be required in the United States. The companies' global operations and overlapping electronics materials portfolios may also trigger merger control reviews in the EU and other major jurisdictions. Competitive effects in semiconductor chemicals, advanced packaging inputs, and data center thermal management markets are likely areas of focus.

KAP Scan — July 12, 2026

A scan of the Public Disclosure Platform (KAP) as of July 12, 2026 shows no new Turkish public company disclosures in the merger/demerger, spin-off, or tender offer categories that are connected to this transaction. No Turkish-listed entity has filed a material event disclosure referencing Solstice Advanced Materials or Element Solutions as of this date.

This is consistent with the transaction's profile: both Solstice and Element Solutions are U.S.-listed companies, and the transaction does not involve a Turkish public company as a direct party. Turkish companies with supply chain exposure to either entity's specialty chemicals portfolios should continue to monitor integration developments through their own procurement and vendor management channels.

This update is provided for informational purposes only and does not constitute legal advice. Transaction details are based on publicly available information as of the publication date. For legal advice regarding M&A transactions, cross-border investments, or U.S. regulatory matters, please contact ULF New York.

Explore Topics

#M&A#advanced-materials#specialty-chemicals#semiconductor#AI#data-center#Solstice#Element-Solutions#HSR#antitrust#KAP#Turkey#update
U

Written by

ULF New York

ULF New York legal team — New York-based attorneys advising Turkish companies and investors on U.S. market entry, corporate law, real estate, and international trade.

Share this article

X
ULF New York Bülteni

ABD Hukuk Rehberlerini
Doğrudan Alın

E-posta adresiniz yalnızca ULF New York hukuki içerikleri için kullanılır. İstediğiniz zaman aboneliğinizi iptal edebilirsiniz.

Related analysis and guides

Further Reading

M&A & Corporate Transactions7 min read

Solstice Advanced Materials to Acquire Element Solutions for Approximately $14.5 Billion

Solstice Advanced Materials has entered into a definitive agreement to acquire Element Solutions in a cash-and-stock transaction valued at approximately $14.5 billion including net debt. The combination creates a scaled advanced materials and specialty chemicals platform spanning semiconductor manufacturing, advanced packaging, AI data center cooling, and thermal management.

Read article
M&A & Corporate Transactions6 min read

Solstice Advanced Materials to Acquire Element Solutions for Approximately $14.5 Billion

Solstice Advanced Materials has announced a definitive agreement to acquire Element Solutions Inc. for approximately $14.5 billion in enterprise value — a mixed cash-and-stock transaction offering Element shareholders $10.00 per share in cash plus 0.5 shares of Solstice. The deal creates a specialty chemicals and advanced materials platform with approximately $29 billion in combined enterprise value and $6.8 billion in annual sales, targeting AI infrastructure, semiconductor manufacturing, and data center thermal management markets.

Read article
M&A & Corporate Transactions9 min read

Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for Approximately $10 Billion

Vertex Pharmaceuticals Inc. has announced a definitive agreement to acquire Crinetics Pharmaceuticals Inc. for approximately $10 billion in an all-cash transaction — $85 per share, representing a premium of approximately 102% to Crinetics' closing price. The deal brings Vertex a commercial-stage rare endocrine disease franchise anchored by FDA-approved Palsonify and a late-stage pipeline asset in congenital adrenal hyperplasia, with combined peak annual sales potential projected above $5 billion.

Read article
M&A & Corporate Transactions9 min read

Perfect Corp. to Go Private in Founder-Led Buyout at $2.00 Per Share

Perfect Corp. (NYSE: PERF), the AI-powered beauty and fashion technology company, has agreed to be taken private by ProjectNY — an acquisition vehicle controlled by founder and Chairman Alice H. Chang — at $2.00 per share in cash. The offer represents a premium of approximately 48.1% over the closing price on March 17, 2026, the last trading day before the initial non-binding proposal. The transaction is expected to close in Q4 2026, subject to shareholder approval and customary closing conditions.

Read article

Published

Sunday, July 12, 2026

Back to Publications